retatrutide type 2 diabetes More data on dropped today at the ADA conference!! Reta is an investigational -not FDA approved yet- once-weekly medication that simultaneously activates the GIP, GLP-1, and glucagon receptors In the Phase Retatrutide Benefits: 24% Weight Loss

Participants on 5 mg lost 16%

The women all lost substantial weight while on the drug

The observed reduction in the respiratory quotient (RQ) after L-carnitine (LC) administration, as measured in our experimental protocol, compared to the "classic" protocol, indicates a shift in metabolic processes toward increased fat oxidation

It also has been found that extensive mitochondrial fission and defective mitochondrial fusion contribute to kidney diseases

Additionally, glutamine-derived aspartate plays a crucial role in hypoxic environments or environments with electron transport chain (ETC) impairment 28

Available from: Montgomery, M., Ahadian, S., Davenport Huyer, L., Lo Rito, M., Civitarese, R